Epigallocatechin-3-gallate inhibits transforming-growth-factor-β1-induced collagen synthesis by suppressing early growth response-1 in human buccal mucosal fibroblasts

J Formos Med Assoc. 2017 Feb;116(2):107-113. doi: 10.1016/j.jfma.2016.01.014. Epub 2016 Feb 24.

Abstract

Background/purpose: Transforming growth factor (TGF)-β is a key regulator in the pathogenesis of oral submucous fibrosis (OSF). Early growth response (Egr)-1 is essential for fibrotic responses to TGF-β. Because TGF-β signaling is cell-type- and context-dependent, we investigated the signaling involved in TGF-β-induced Egr-1 in primary human buccal mucosal fibroblasts (BMFs).

Methods: TGF-β-induced Egr-1 and its signaling were assessed by western blotting in BMFs. Egr-1 small interfering RNA was used to define the role of Egr-1 on TGF-β-induced mRNAs of the α1- and α2-chains of type I collagen (COL1A1 and COL1A2) and acid-soluble collagen production (via Sircol collagen assay). The effects of epigallocatechin-3-gallate (EGCG) on TGF-β-induced Egr-1 protein and acid-soluble collagen were also evaluated.

Results: TGF-β1 stimulated Egr-1 production in BMFs. Pretreatment with PD98059, SP600125, SB431542, and SIS3, but not SB203580, significantly reduced TGF-β1-induced Egr-1 protein expression. Genetic targeting of Egr-1 completely inhibited TGF-β1-induced type I collagen mRNAs and collagen protein expression. EGCG fully inhibited TGF-β1-induced Egr-1 and TGF-β1-stimulated production of acid-soluble collagens.

Conclusion: We conclude that activin receptor-like kinase (ALK)5, Smad3, extracellular signal-regulated kinase, and c-Jun N-terminal kinase are involved in the TGF-β1-induced Egr-1 protein production in BMFs. Egr-1 mediates TGF-β1-induced COL1A1 and COL1A2 mRNA expression and acid-soluble collagen production in BMFs. EGCG can block TGF-β1-induced collagen production by attenuating Egr-1 expression in BMFs. Egr-1 is a key mediator in TGF-β1-induced pathogenesis of OSF. EGCG may be useful in the prevention or treatment of OSF.

Keywords: early growth response-1; epigallocatechin-3-gallate; fibroblast; oral submucous fibrosis; transforming growth factor β.

MeSH terms

  • Anthracenes / pharmacology
  • Benzamides / pharmacology
  • Catechin / analogs & derivatives*
  • Catechin / pharmacology
  • Cells, Cultured
  • Collagen Type I / biosynthesis*
  • Dioxoles / pharmacology
  • Early Growth Response Protein 1 / genetics
  • Early Growth Response Protein 1 / metabolism*
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism*
  • Flavonoids / pharmacology
  • Humans
  • Mouth Mucosa / cytology
  • Oral Submucous Fibrosis / drug therapy
  • Signal Transduction / drug effects
  • Transforming Growth Factor beta1 / pharmacology*

Substances

  • 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide
  • Anthracenes
  • Benzamides
  • Collagen Type I
  • Dioxoles
  • EGR1 protein, human
  • Early Growth Response Protein 1
  • Flavonoids
  • Transforming Growth Factor beta1
  • pyrazolanthrone
  • Catechin
  • epigallocatechin gallate
  • Extracellular Signal-Regulated MAP Kinases
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one